Pyxis Oncology (PYXS)

Executive Summary

Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing novel antibody-drug conjugates (ADCs) and immunotherapies for difficult-to-treat cancers. The company's lead program, PYX-201 (micvotabart pelidotin), is a first-in-concept ADC targeting the tumor extracellular matrix, currently in Phase 1 trials for advanced solid tumors, with a particular focus on head and neck squamous cell carcinoma. Pyxis also has two other clinical-stage programs: PYX-106, a Phase 1 ADC for solid tumors, and APX005M, a CD40 agonist antibody in Phase 1 for CNS tumors. The company's strategy leverages a differentiated portfolio aimed at overcoming tumor resistance and improving patient outcomes. Pyxis Oncology's near-term catalysts include data readouts from its ongoing Phase 1 trials. The PYX-106 trial is expected to complete in May 2026, with initial safety and efficacy data anticipated shortly thereafter. Similarly, the APX005M CNS tumor trial is scheduled to complete in June 2026, which could provide key proof-of-concept data. Additionally, the company may present updated results from the PYX-201 trial at upcoming medical conferences. These milestones are critical for validating Pyxis's ADC platform and could significantly impact the stock's valuation. Given the early stage of development and the high-risk nature of oncology trials, the conviction score is moderate.

Upcoming Catalysts (preview)

• Q3 2026PYX-106 Phase 1 Trial Completion and Data Readout70% success
• Q3 2026APX005M Phase 1 CNS Tumor Trial Completion and Data60% success
• Q4 2026PYX-201 Updated Phase 1 Data Presentation at Medical Conference50% success